| Michael Cradic, DC | |
|
3850 W 16th St Ste C, Yuma, AZ 85364-0753 | |
| (928) 344-2460 | |
| Not Available |
| Full Name | Michael Cradic |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 3 Years |
| Location | 3850 W 16th St Ste C, Yuma, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013663053 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 9144 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cradic Chiropractic Pc | 3870695315 | 2 |
News Archive
[President Barack Obama's] advisors shouldn't be surprised - the success rate for large, multi-million dollar commercial and government IT projects is very low. The Standish Group, which has a database of some 50,000 development projects, looked at the outcomes of multimillion dollar development projects and ran the numbers for Computerworld. Of 3,555 projects from 2003 to 2012 that had labor costs of at least $10 million, only 6.4% were successful. The Standish data showed that 52% of the large projects were "challenged," meaning they were over budget, behind schedule or didn't meet user expectations. The remaining 41.4% were failures - they were either abandoned or started anew from scratch (Patrick Thibodeau, 10/21).
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).
People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.
A quick screening method has been used for the first time in a standard open laboratory to identify and test promising anti-Ebola drugs. This approach increases the possibility of finding new therapies faster.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
› Verified 2 days ago
| Provider Name | Cradic Chiropractic Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1548364862 PECOS PAC ID: 3870695315 Enrollment ID: O20070301000462 |
News Archive
[President Barack Obama's] advisors shouldn't be surprised - the success rate for large, multi-million dollar commercial and government IT projects is very low. The Standish Group, which has a database of some 50,000 development projects, looked at the outcomes of multimillion dollar development projects and ran the numbers for Computerworld. Of 3,555 projects from 2003 to 2012 that had labor costs of at least $10 million, only 6.4% were successful. The Standish data showed that 52% of the large projects were "challenged," meaning they were over budget, behind schedule or didn't meet user expectations. The remaining 41.4% were failures - they were either abandoned or started anew from scratch (Patrick Thibodeau, 10/21).
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).
People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.
A quick screening method has been used for the first time in a standard open laboratory to identify and test promising anti-Ebola drugs. This approach increases the possibility of finding new therapies faster.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Cradic, DC 10150 E 33rd St, Yuma, AZ 85365-6012 Ph: () - | Michael Cradic, DC 3850 W 16th St Ste C, Yuma, AZ 85364-0753 Ph: (928) 344-2460 |
News Archive
[President Barack Obama's] advisors shouldn't be surprised - the success rate for large, multi-million dollar commercial and government IT projects is very low. The Standish Group, which has a database of some 50,000 development projects, looked at the outcomes of multimillion dollar development projects and ran the numbers for Computerworld. Of 3,555 projects from 2003 to 2012 that had labor costs of at least $10 million, only 6.4% were successful. The Standish data showed that 52% of the large projects were "challenged," meaning they were over budget, behind schedule or didn't meet user expectations. The remaining 41.4% were failures - they were either abandoned or started anew from scratch (Patrick Thibodeau, 10/21).
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).
People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.
A quick screening method has been used for the first time in a standard open laboratory to identify and test promising anti-Ebola drugs. This approach increases the possibility of finding new therapies faster.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
› Verified 2 days ago
Southwest Pain Associates-yuma, Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 11551 S Fortuna Rd, Suite C, Yuma, AZ 85367 Phone: 928-342-7220 Fax: 928-342-7223 | |
Dr. Scott Mcgill Norris, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 11551 S Fortuna Rd, Ste. B, Yuma, AZ 85367 Phone: 928-342-7220 Fax: 928-342-7223 | |
Aqua Chiropractic & Day Spa Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 3970 W 24th St, Suite 104, Yuma, AZ 85364 Phone: 928-782-1818 Fax: 888-899-2073 | |
Dr. Mark A. Corbin, N.M.D.,D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 144 W 32nd St, Yuma, AZ 85364 Phone: 928-726-8847 Fax: 928-341-0417 | |
Dr. Zeyad Danny Aboul-hosn, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 3970 W 24th St, Suite104, Yuma, AZ 85364 Phone: 928-782-1818 | |
Dr. Renee Cauvin, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 144 W 32nd St, Yuma, AZ 85364 Phone: 928-726-8847 Fax: 928-341-0417 |